

# Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

THOUSAND OAKS, Calif.--(BUSINESS WIRE)-- [Atara Biotherapeutics, Inc.](#) (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of inducement awards to Ricardo Fonseca, its new Vice President, Operations.

The Compensation Committee of Atara's Board of Directors granted Mr. Fonseca 60,000 restricted stock units of Atara's common stock and time-based stock options to purchase 69,000 shares of Atara's common stock under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of December 12, 2022, as an inducement material to the new employee entering into employment with Atara, in accordance with Nasdaq Listing Rule 5635(c)(4).

The restricted stock units vest over four years, with 25 percent vesting on the first quarterly vesting date after the first anniversary of the vesting commencement date and the remainder vesting in 12 approximately equal quarterly installments over the following three years, subject to the employee being continuously employed by Atara as of such vesting dates. The time-based stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments over the following three years, subject to Mr. Fonseca being continuously employed by Atara as of such vesting dates. The stock options have a ten-year term and an exercise price of \$4.32 per share, equal to the per share closing price of Atara's common stock as reported by Nasdaq on December 12, 2022.

Atara is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).

## About Atara Biotherapeutics, Inc.

[Atara Biotherapeutics, Inc. \(@Atarabio\)](#) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune disease. With our lead program receiving a CHMP positive opinion for a marketing authorization in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel® (tabelecleucel) in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTL); ATA188, a T-cell

immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Improving patients' lives is our mission and we will never stop working to bring transformative therapies to those in need. Atara is headquartered in Southern California. For additional information about the company, please visit [atarabio.com](http://atarabio.com) and follow us on [Twitter](#) and [LinkedIn](#).

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20221213006114/en/>

## **INVESTOR & MEDIA:**

### ***Investors***

Eric Hyllengren

805-395-9669

[ehyllengren@atarabio.com](mailto:ehyllengren@atarabio.com)

### ***Media***

Alex Chapman

805-456-4772

[achapman@atarabio.com](mailto:achapman@atarabio.com)

Source: Atara Biotherapeutics, Inc.